PA clinic for gestational diabetes: An observational study

Nikki Semaniuk1, Abigail Meadows, Pam Katz

  • 1At the University of Manitoba in Winnipeg, Manitoba, Canada, Nikki Semaniuk is a clinical instructor for the Master of Physician Assistant Studies program; Abigail Meadows is a first-year medical resident; Pam Katz is an assistant professor in the Department of Internal Medicine and section head for the Section of Endocrinology; Sora Ludwig is a professor; Bruce Roe is an assistant professor of endocrinology and metabolism; Elizabeth Salamon is an assistant professor; Sarah M. Sigurdson is a first-year medical student; Katherine J. Bernier is a first-year medical student; Christy Pylypjuk is an associate professor and associate head of research in the Department of Obstetrics, Gynecology and Reproductive Sciences, as well as the assistant director of the Manitoba Obstetrical Outreach Program; and Jennifer M. Yamamoto is an assistant professor in the Department of Internal Medicine. Outside of the University of Manitoba, N. Semaniuk is an endocrinology PA at St. Boniface Hospital in Winnipeg; P. Katz is medical director of the Manitoba Adult Insulin Pump Program at Health Sciences Centre Winnipeg in Winnipeg; and J.M. Yamamoto is an adjunct assistant professor in the Department of Medicine at the University of Calgary in Calgary, Alberta, Canada. E. Salamon discloses receipt of monetary compensation from Novo Nordisk for educational sessions. C. Pylypjuk discloses receipt of grants to University of Manitoba and Health Sciences Centre Foundation for unrelated work. J.M. Yamamoto discloses receipt of devices for no or reduced cost from Abbott and Medtronic for investigator-initiated and publicly funded studies. The authors have disclosed no other potential conflicts of interest, financial or otherwise.

Summary

Physician associate-led clinics effectively manage gestational diabetes, showing comparable maternal and neonatal outcomes to physician-led care. This model offers a safe and efficient approach to managing this common pregnancy complication.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.1K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
783
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
793